M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Xencor doses first subject under Phase 1 study of XmAb7195 for asthma
Biopharmaceutical company Xencor (NasdaqGM:XNCR) disclosed on Wednesday that it has dosed its first subject under a Phase 1a clinical trial of XmAb7195 for treating asthma.
The company added that XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives